Use of motherwort in the preparation of medicines for preventing and treating inflammation-related diseases

A technology of leonurine and anti-inflammation, applied in the direction of drug combination, antipyretic, anti-inflammatory agent, etc., can solve the problem that the effect of leonurine has not been reported.

Active Publication Date: 2011-11-30
ZHUHAI HENGQIN NEW DISTRICT ZHONGZHU ZHENGTAI MEDICAL MANAGEMENT CO LTD
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Leonurine (Leonurine) is a specific component of traditional Chinese medicine Leonurine. It has been reported that Leonurine can significantly inhibit the contraction of vascular smooth muscle by in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of motherwort in the preparation of medicines for preventing and treating inflammation-related diseases
  • Use of motherwort in the preparation of medicines for preventing and treating inflammation-related diseases
  • Use of motherwort in the preparation of medicines for preventing and treating inflammation-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Protective Effect of Leonurine on Inflammatory Response of Human Umbilical Vein Endothelial Cells in Vitro

[0028] Grouping: Divide 1×10 5 Endothelial cells or cardiomyocytes were seeded into a 6cm culture dish and cultured for 3 days to reach 85-90%, and the cells were synchronized for 6-12 hours. They were randomly divided into 6 groups, namely: ① normal control group; ② model group; ③ low-dose leonurine group; ④Middle-dose Leonurine group; ⑤High-dose Leonurine group; ⑥Positive drug group. Administration: ③-⑤ adding leonurine with a final concentration of 5 μM, 10 μM, 20 μM, ⑥ dexamethasone 10 μM, and incubate for 4 hours. Add TNF-α (10ng / ml) to induce endothelial cell inflammatory response. The mRNA was extracted, and real time RT-PCR was used to measure the transcription levels of inflammation-related genes. Inflammation-related genes determined: VCAM-1, MCP-1, iNOS, COX-2. The experimental data were analyzed by one-way analysis of variance, p<0.05, t...

Embodiment 2

[0030] Example 2 Effect of Leonurine on the Regulatory Mechanism of TNF-α-Induced Endothelial Cell Inflammation Response

[0031] Grouping: Divide 1×10 5 Endothelial cells or cardiomyocytes were seeded into a 6cm culture dish and cultured for 3 days to reach 85-90%, and the cells were synchronized for 6-12 hours. They were randomly divided into 6 groups, namely: ① normal control group; ② model group; ③ low-dose leonurine group; ④Middle-dose Leonurine group; ⑤High-dose Leonurine group; ⑥Positive drug group. Administration: ③-⑤ adding leonurine with a final concentration of 5 μM, 10 μM, 20 μM, ⑥ dexamethasone 10 μM, and incubate for 4 hours. After adding TNF-α (10ng / ml) for 15min, the cell protein was collected, and Western blotting was used to measure the activation of MAPK (p38, ERK1 / 2, JNK1 / 2) and NF-κBp65. The results showed that Leonurine inhibited the effect of TNF-α on The activation of the signaling pathway p38MAPK inhibits the activation and translocation of the trans...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention, belonging to the Chinese Pharmaceutical field, relates to applications of specific monomer leonurine of Chinese medicinal herb Leonurus heterophyllus in preparing pharmaceutical compositions, in particular to applications in preparing pharmaceutical compositions for preventing inflammation-related diseases. The results of in vitro inflammatory model tests show that the leonurine can prevent the transcription and expression of inflammatory mediators, reduce the release of nitric oxide induced by inflammations, and define the regulation mechanism of leonurine in preventing inflammatory mediators. The tests prove that the leonurine has obvious anti-inflammatory action on inflammation-related diseases, and can be used for preparing medicines for preventing inflammation-related diseases.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the application of the specific monomer leonurine in the Chinese herbal medicine Leonurus in the preparation of pharmaceutical compositions, especially the application in the preparation of pharmaceutical compositions for preventing and treating inflammation-related diseases. Background technique [0002] At present, studies have confirmed that inflammatory response is one of the primary pathogenic factors of ischemic heart disease, and always plays an important role in its occurrence, development and prognosis. Inflammation in ischemic myocardium is a cause of endothelial and cardiomyocyte dysfunction, as well as of oxidative stress in the myocardium. Intervention of its immune-related inflammatory response will effectively prevent the occurrence and development of myocardial ischemia injury. The myocardial dysfunction caused by ischemia can be effectively pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/235A61P29/00
Inventor 朱依谆刘新华潘礼龙
Owner ZHUHAI HENGQIN NEW DISTRICT ZHONGZHU ZHENGTAI MEDICAL MANAGEMENT CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap